When healthcare innovation drives you, the possibilities are endless. Like many successful healthtech entrepreneurs, Gordon Saul has worn many hats throughout his career, experiencing the industry from many different angles. Today, he is an integral part of an incredibly talented team as executive director at Stanford Byers Center for Biodesign, an organization that we are honored to have been partnering and collaborating with for many years.
“My advice for you is to use your very best judgment in making life’s major decisions; follow your passion and your heart as you embark on life’s wonderful journey that lies ahead of you. Pursue your dreams until the day you die. Don’t take yourself too seriously and laugh every single day. Live your life ‘The Carolina Way,’ with hard work,
“We were given a gift to be able to solve a big problem, and though the road to getting a device to market is often a bumpy one, we have never lost our resolve to keep moving forward.”
That focus from Madorra, a Fogarty Institute graduate aiming to improve the quality of life for breast cancer survivors and post-menopausal women,
The growing size and influence of the much-anticipated 38th Annual J.P. Morgan Healthcare Conference continues to drive high attendance and concurrent events. This year, the Fogarty Institute played a larger role by hosting its first Innovator’s reception in partnership with Stanford Biodesign, The MedTech Strategist, RCT and the MedTech Innovator.
The reception was a success,
The Fogarty Institute continues to build its bench strength with the recent hire of seasoned medtech leader Marga Ortigas-Wedekind as chief commercial strategy officer. With 30 years of experience in medical and health technology companies at a variety of stages of development, her expertise will make her an asset to the entire team, most notably to our entrepreneurs,
With a goal of helping bring together investors and collaborators in the global medtech industry and shine a light on continuing education, the Fogarty Institute once again participated in the prestigious MedTech Strategist Innovation Summit San Francisco 2019 on November 18 and 19; this year assuming a larger role as a co-sponsor and co-organizer. As in the past,
One of Dr. Fogarty’s strengths when forming new companies was a focus on hiring experts in the field who had the ability to both embrace and expand on his vision. Such was the case when he asked Gary Kalbach to help him start the Fogarty Institute for Innovation in 2007. He became founding president and chair of the board,
“I don’t believe in the concept of the ‘lone genius’ that journalists like to highlight when writing about the success of a company – it’s really the teams that win.”
This year’s 21stAnnual Thomas J. Fogarty, MD, Lecture held at Stanford University, featured Brook Byers, founding partner of Kleiner Perkins.
Going to the doctor is not always a preferred activity, and part of that is the testing involved, including, of course, the ubiquitous urine test. This remains a standard method used to determine the proper course of treatment for patients and to prevent exposure to potentially harmful medications and procedures. Point-of-care urine tests are used to diagnose a range of conditions,
Entrepreneurship runs in Fletcher Wilson’s veins – quite literally. As founder and CEO of InterVene, a Fogarty Institute graduate that has developed a minimally invasive device for the treatment of severe venous disease in the legs, Fletcher has many of the traits that make a successful leader and innovator. That includes a penchant for identifying problems and finding solutions,